CLEVELAND, OHIO – (April 27, 2020) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, today announced that Dr. Anthony Maida has decided to resign from its Board of Directors.

Dr. Maida had served on Vitality’s Board of Directors since 2012 and had served as chairman of its Audit

Committee most recently. “Dr. Maida has made a major contribution to the strength and breadth of Vitality’s suite of cannabinoid-based pharmaceutical products,” said Vitality’s CEO, Michael Cavanaugh. “We are grateful for his years of dedication to our venture and will miss his thoughtful insight and guidance as we move forward.” Vitality’s Executive Chairman Edward Feighan, added, “Dr. Maida is a respected and renown figure in pharmaceutical clinical development. Vitality’s sound approach to clinical development benefited from his experienced and cautious oversight. We will remain grateful for his dedication and foresight.”

“I leave the board of Vitality with confidence in the stewardship of its current management and board members,” commented Dr. Maida. “And I remain enthusiastic about the potential for cannabinoid-based pharmaceuticals.”


Vitality Biopharma, Inc.
Investor Relations
(530) 231-7800

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

News and Events

Range Impact Reports 1Q 2024 Financial Results

CLEVELAND, OHIO – (May 15, 2024) – Range Impact, Inc. (OTC: RNGE) (“Range...

read more
Range Impact Transitions Two Executives to Graphium Biosciences Subsidiary as Part of Proposed Divestiture and Promotes Corporate Controller to Chief Financial Officer

CLEVELAND, OHIO – (April 26, 2024) – Range Impact, Inc. (OTC: RNGE)...

read more
Range Impact Reports 4Q 2023 and Full Year 2023 Financial Results

CLEVELAND, OHIO – (March 29, 2024) – Range Impact, Inc. (OTC: RNGE)...

read more